Largest Cancer Fighters Companies By Total Asset

Total Asset
Total AssetEfficiencyMarket RiskExp Return
1BDX Becton Dickinson and
57.29 B
 0.03 
 1.36 
 0.04 
2REGN Regeneron Pharmaceuticals
37.76 B
(0.07)
 1.87 
(0.13)
3ARGX argenx NV ADR
4.54 B
 0.02 
 1.47 
 0.03 
4HALO Halozyme Therapeutics
2.06 B
 0.23 
 1.49 
 0.34 
5ARRY Array Technologies
1.71 B
(0.05)
 5.22 
(0.26)
6PTCT PTC Therapeutics
1.71 B
 0.05 
 2.70 
 0.13 
7HCM HUTCHMED DRC
1.28 B
(0.01)
 3.09 
(0.04)
8NVCR Novocure
1.24 B
(0.19)
 3.53 
(0.68)
9ZLAB Zai Lab
1.19 B
 0.11 
 2.83 
 0.32 
10BPMC Blueprint Medicines Corp
1.18 B
 0.01 
 3.43 
 0.04 
11IOVA Iovance Biotherapeutics
910.43 M
(0.28)
 4.17 
(1.17)
12CLDX Celldex Therapeutics
792.34 M
(0.16)
 2.74 
(0.43)
13MESO Mesoblast
669.15 M
 0.12 
 7.36 
 0.90 
14GERN Geron
593.78 M
(0.25)
 4.99 
(1.23)
15FGEN FibroGen
423.53 M
 0.04 
 9.15 
 0.35 
16CLLS Cellectis SA
334.27 M
(0.09)
 6.32 
(0.57)
17TGTX TG Therapeutics
329.59 M
(0.06)
 3.36 
(0.20)
18ANGO AngioDynamics
317.67 M
 0.10 
 6.30 
 0.61 
19AGEN Agenus Inc
313.91 M
(0.06)
 5.37 
(0.31)
20MGNX MacroGenics
298.42 M
(0.17)
 3.51 
(0.61)
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value. Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.